Proactive Investors - Run By Investors For Investors

ReNeuron wins Breakthrough of the Year at 2019 Mediscience Awards

ReNeuron said it looks forward to "continuing to advance our clinical and business development activities in the months ahead".
The group is "greatly encouraged" by the progress it has made

ReNeuron Group PLC (LON:RENE) has won the Breakthrough of the Year award at the 2019 Mediscience Awards in London for the clinical development and commercial progress it has made over the past year.

The developer of stem cell technologies said the award acknowledges positive data from its ongoing phase I/II clinical trial of its hRPC treatment for a rare blindness-causing disease called retinitis pigmentosa.

READ: ReNeuron well funded for pivotal period clinically and commercially

Another recent highlight for the group was the signing of an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and commercialisation of ReNeuron's cell therapy programmes in China.

"We are delighted to have been awarded the Breakthrough of the Year award at the 2019 European Mediscience Awards,” said ReNeuron chief executive Olav Hellebø.

“We are greatly encouraged by the progress we have made with our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability over the past year and look forward to continuing to advance our clinical and business development activities in the months ahead."

View full RENE profile View Profile

ReNeuron Group PLC Timeline

Related Articles

Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use